AbbVie has submitted a marketing authorisation application (MAA) to the European Medicines Agency (EMA) for atogepant as a migraine treatment for adults who have at least four migraine days per month.
Atogepant is an oral calcitonin gene-related peptide (CGRP) inhibitor. If approved, it would be the first daily oral CGRP receptor antagonist migraine treatment for adults in Europe.
![Het beste uit je content halen met een kloppend verhaal [10 stappen]](https://www.pharmamarketeer.nl/wp-content/uploads/2024/12/businesswoman-working-at-creative-office-2023-11-27-05-24-05-utc-1-80x60.jpg)
